Who is sponsoring NCT07411144?

NCT07411144 is sponsored by National Cancer Institute, Egypt.

What drugs are being tested in NCT07411144?

Interventions in NCT07411144: Gemcitabine (1000 mg/m2).

What condition does NCT07411144 study?

NCT07411144 studies Diffuse Pleural Mesothelioma (DPM).

Is NCT07411144 still recruiting?

NCT07411144 is currently completed. Last updated 13 February 2026.

Last reviewed 2026-02-13 · How we verify

NCT07411144: GEMO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma

Completed Phase 2 Last updated 13 February 2026

What this trial tests

Phase 2 trial testing Gemcitabine (1000 mg/m2) in Diffuse Pleural Mesothelioma (DPM) in 64 participants. Completed in 15 March 2023.

Timeline

15 March 2020

Primary endpoint
15 March 2023

15 March 2023

Quick facts

Lead sponsor	National Cancer Institute, Egypt
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	64
Start date	15 March 2020
Primary completion	15 March 2023
Estimated completion	15 March 2023
Sites	1 location across Egypt

Drugs / interventions tested

Gemcitabine (1000 mg/m2)

Conditions studied

Diffuse Pleural Mesothelioma (DPM) — all drugs for Diffuse Pleural Mesothelioma (DPM) →

Sponsor

National Cancer Institute, Egypt

Who can join

18 and older, any sex, with Diffuse Pleural Mesothelioma (DPM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

What is this study about? This study looks at whether continuing chemotherapy with a drug called gemcitabine after initial treatment can help patients with diffuse pleural mesothelioma keep their cancer under control for a longer time. Diffuse pleural mesothelioma is a rare and aggressive cancer that affects the lining of the lungs. Even after standard chemotherapy, the disease often comes back quickly. Doctors are therefore looking for maintenance treatments that may delay cancer progression. What does this mean for patients and families? Gemcitabine maintenance treatment may help delay cancer progression It does not clearly extend overall life expectancy Side effects are common and should be carefully discussed with the treating oncologist Treatment decisions should consider: Patient performance status Symptoms Personal preferences and quality of life What does this mean for health care providers? Gemcitabine maintenance may be an option for: Fit patients Those who responded to first-line chemotherapy Careful patient selection is essential Monitoring for hematologic toxicity is required Further larger studies are needed to confirm survival benefit

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.
Sobeih ME, Helal M, Yahia M, Khorshid O. · · 2026 · PMID 41888696 · DOI 10.1186/s12885-026-15836-3

Verify or expand the search:

Other trials of Gemcitabine (1000 mg/m2)

Trials testing the same drug.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07272109 — Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes · Phase 3 · not yet recruiting

Other National Cancer Institute, Egypt trials

Trials by the same sponsor.

NCT07424638 — Interscalene Block Versus Anterior Suprascapular Block for Post-Thoracotomy Shoulder Pain · NA · recruiting
NCT07367581 — Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer · NA · recruiting
NCT07367568 — Costotransverse Foramen Block With Erector Spinae Plane Block in Modified Radical Mastectomy · NA · recruiting
NCT07337330 — Ultrasound Guided External Oblique Intercostal Plane Block Versus Erector Spinae Block for Post Hepatectomy Pain · NA · not yet recruiting
NCT07390448 — Rhomboid Intercostal Sub-serratus Plane Blocks and Erector Spinae Plane Block in Mastectomy Surgeries · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07411144 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute, Egypt
Last refreshed: 13 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07411144.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing